http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016094677-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faac94e5aab14c5cda008983f6aeb95d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c80c1e3e9816af48f8d62446b6d9121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eef41b2e33063c72aaed41687ad51e94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c959fb181ed157b8ef7b81cfd902437
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-213
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-712
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B53-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-22
filingDate 2015-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80091c7463216e90c3a9e73bd0e495ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdbdd8373ccb91ec8ff8e4a6168da98a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9edb6ab835799ede3c3c8e058415710
publicationDate 2016-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2016094677-A3
titleOfInvention Mononucleotides having a bioreversible disulfide group
abstract The invention features a mononucleotide comprising a nucleobase bonded to a sugar having a 3'-carbon and a 5'-carbon, where the 5'-carbon is bonded to a phosphorus (V) atom of a phosphate group through an oxygen atom, the phosphorus (V) atom being bonded to (i) a disulfide bioreversible group through an oxygen atom; and (ii) (a) optionally substituted amino, optionally substituted alkoxy, optionally substituted aryloxy, or optionally substituted heteroaryloxy; or (b) the 3'-carbon through an oxygen atom. The invention also features methods of delivering the mononucleotide to a cell and methods of treating a subject having Hepatitis C.
priorityDate 2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014309413-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8846881-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2610264-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013126034-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012012465-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396401
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457623688
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397646

Total number of triples: 40.